Cartesian Therapeutics
RNAC
69 hedge funds and large institutions have $58.3M invested in Cartesian Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 32 reducing their positions, and 15 closing their positions.
54% more capital invested
Capital invested by funds: $38M → $58.3M (+$20.3M)
0.06% less ownership
Funds ownership: 1.18% → 1.13% (-0.06%)
14% less funds holding
Funds holding: 80 → 69 (-11)
56% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 32
73% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.69M |
| 2 |
Millennium Management
New York
|
+$550K |
| 3 |
Invesco
Atlanta,
Georgia
|
+$134K |
| 4 |
Jane Street
New York
|
+$73.8K |
| 5 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$60.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.54M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$656K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$514K |
| 4 |
MAP
Madison Avenue Partners
New York
|
-$402K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$302K |
RNAC Hedge Fund Activity: Q1 2024 in Review
69 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2024, worth a combined $58.3M — up 54% from $38M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of RNAC and 4 opened new positions — a net loss of 11 holders — while 32 trimmed existing stakes and 14 added.
The largest buyer was Fidelity Investments, adding an estimated $4.69M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $1.54M sold.
- 69 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2024, down from 80 in Q4 2023.
- Funds reported $58.3M of Cartesian Therapeutics stock for Q1 2024, up 54% quarter-over-quarter.
- 4 funds opened new Cartesian Therapeutics positions in Q1 2024 and 15 closed out, a net change of -11 holders.
- The largest Cartesian Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $4.69M added.
- The largest Cartesian Therapeutics seller in Q1 2024 was Nantahala Capital Management, an estimated $1.54M sold.
Based on aggregated 13F filings for Q1 2024.